ReviewRecent advances in drug delivery and formulation2025
A Comprehensive Review of Nanostructured Lipid Carriers: Innovations and Applications in Breast Cancer Treatment.
Review in Recent advances in drug delivery and formulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostructured Lipid Carriers (NLCs) represent a promising advancement in the treatment of breast cancer, addressing the significant challenges posed by conventional chemotherapy, such as poor drug solubility, short half-lives, and high toxicity. This review delves into the potential of NLCs to overcome these limitations, highlighting their unique structure comprising a solid and lipid liquid core stabilized by surfactants. By examining diverse lipid blends used in the preparation of NLCs, the article emphasizes their suitability for targeted drug delivery. Various facets of NLC configuration, categorization, composition, and formulation approaches are systematically explored to provide a comprehensive understanding of their attributes. The findings reveal that NLCs possess a high capacity for lipophilic drugs and offer advantages over traditional lipid-based nanocarriers. The review underscores the pivotal role of NLCs in enhancing drug delivery efficiency for breast cancer therapy while minimizing systemic toxicity. Conclusively, this review positions NLCs as a key player in the evolution of drug delivery systems for breast cancer treatment, providing a detailed outlook on their transformative potential and contributing to a nuanced understanding of their significance in advancing the field of breast cancer treatment.
Indexed as
Identifiers
39660493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.